What is it about?

Newly available treatment for late-onset Pompe disease

Featured Image

Why is it important?

review of a therapy approved by both the FDA and European regulatory agencies


May patients on ERT will switch to this newly available drug

Prof Corrado Angelini
Universita degli Studi di Padova Polo Bibliotecario di Scienze Farmacologia e Scienze Farmaceutiche

Read the Original

This page is a summary of: Evaluating avalglucosidase alfa for the management of late-onset Pompe disease, Expert Review of Neurotherapeutics, January 2024, Taylor & Francis,
DOI: 10.1080/14737175.2024.2306855.
You can read the full text:



The following have contributed to this page